Global Microbiome Therapeutics Market 2022: United States Projected to be the Dominant Regional Market

The microbiome therapeutics market is a segment of the pharmaceutical industry focused on the development and production of drugs and therapies that target the human microbiome. The human microbiome refers to the community of microorganisms that live in and on the human body, including bacteria, viruses, fungi, and other microorganisms. These microorganisms play a critical role in maintaining health and wellness, and an imbalance in the microbiome has been linked to a number of diseases and conditions. As a result, the market for microbiome therapeutics is expected to continue growing as researchers and pharmaceutical companies develop new treatments and therapies to address imbalances in the microbiome.

Request For Free Sample Report of "Microbiome Therapeutics Market"@ https://www.persistencemarketresearch.com/samples/7990

According to the latest market report published by Persistence Market Research, titled 'Microbiome Therapeutics Market Potential: Global Pipeline Analysis and Assessment 2018 - 2025', the global microbiome therapeutics market is expected to exhibit an exponential CAGR of 62.9% during the forecast period 2018-2025.

Persistence Market Research estimates that the global market for microbiome therapeutics is expected to be valued at US$ 10.1 Mn in 2018 and is expected to reach US$ 897.3 Mn by 2025 end. Need for reliable, precise and fast treatment options for certain diseases, such as C. difficile infection (CDI), hepatic encephalopathy and multidrug resistant urinary tract infection creates a huge potential for the growth of the microbiome therapeutics market. Breakthrough therapy designation and orphan drug approvals for microbiome therapeutics is expected to accelerate the launch of developmental drugs in the microbiome therapeutics market. A huge pipeline with over 120 candidates in different stages of development further creates the platform for potential growth of the microbiome therapeutics market.

More Than 120 Drugs Are in the Pipeline in the Global Microbiome Therapeutics Market

At present there are no marketed microbiome therapeutics in the global market; however, the first drug is expected to be launched in 2018. The global market is dominated by over 25 companies with more than 120 drugs in the pipeline at different stages of development. However, over 60% of these drugs are in the discovery or preclinical phase, where there is high uncertainty surrounding the success of these molecules to reach the clinical phase and being launched as a new drug molecule. Majority of the pipeline drugs are being developed for gastrointestinal disorders and contribute approximately 28.7% of the total pipeline products.

Research and development in the microbiome industry is prominently dependent on government funding and research grants. Formation of policies and provision of subsidy by various governments encourages research and development activities across various segments of the research including discovery and clinical research. Government initiatives in funding microbiome research is the preliminary factor driving revenue growth of global microbiome therapeutics market. For instance, the U.S. government had allocated US$ 1.6 Bn for microbiome R&D programs in 2016 & 2017.

Buy Full Report Now and Get Up to 20% Discount @ https://www.persistencemarketresearch.com/checkout/7990

Global Microbiome Therapeutics Market: Segmentation and Forecast

The market is segmented based on indication and region. On the basis of indication, the market has been segmented into type 2 diabetes, obesity, C. difficile infection and primary hyperoxyurea. C. difficile infection indication segment is expected to contribute the highest market share of over 34% by 2025 end. More number of product approvals for CDI is attributed to a high share of the C. difficile infection segment in the global market.

Human gut is home to over 100 Tn bacteria, containing thousands of different species. Long-term exposure to antibiotics causes dysbiosis in gut microbial composition, which leads to a variety of gastrointestinal disorders including CDI, ulcerative colitis, IBD, bacterial infection and even antibiotic associated diarrhea. Microbiome therapeutics however, present an excellent option for the treatment of CDI and other gastrointestinal disorders, as they are designed to naturally cure dysbiosis and bring the microbiome system back to normal functioning.

Global Microbiome Therapeutics Market: Regional Forecast

On the basis of region, the market has been segmented into the U.S., Europe, Japan and Rest of the World (RoW). U.S. is estimated to contribute the highest share of over 44% by 2025 end, due to early launch of microbiome therapeutics and high penetration compared to other markets. The market in Japan is expected to witness delayed growth due to the complex regulatory pathways for new biological drugs. The microbiome therapeutics market in the rest of the world is expected to show gradual acceptance of "bug medicine", Canada being the most lucrative among the rest of the world countries.

Global Microbiome Therapeutics Market: Competitive Landscape

Key players identified in the global microbiome therapeutics market are SERES Therapeutics Inc., Rebiotix Inc., OxThera AB, Immuron Ltd., Microbiome Therapeutics Inc., Ferring B.V., Ritter Pharmaceuticals, LNC Therapeutics, Enterome SA, Synlogic Inc., 4D Pharma Plc. AOBiome LLC, Vedanta Biosciences Inc., ViThera Pharmaceuticals Inc., AvidBiotics, Osel Inc. etc. among others.

Request Customization @ https://www.persistencemarketresearch.com/request-customization/7990

Key Questions Answered in This Report.

What are the Roadblocks for Microbiome Therapeutics Market Suppliers?
What are the Key Opportunities for Microbiome Therapeutics Market Manufacturers?
How is Focus on Safety Influencing Microbiome Therapeutics Market Demand?
What is the Regulatory Impact on Global Sales of Microbiome Therapeutics Market?
Which Region Offers the Largest Opportunity for Sales of Microbiome Therapeutics Market?
Where Does the U.S. Stand in the Market for Microbiome Therapeutics Market?
What Is the Outlook for Microbiome Therapeutics Market Manufacturers in China?
Why is Germany a Lucrative Market for Microbiome Therapeutics Market Manufacturers?
Why Will Belgium Outpace Other European Markets for Microbiome Therapeutics Market?
Why is There High Demand for Tires in Microbiome Therapeutics Market?
Why are Sales of Microbiome Therapeutics Market Surging?

Related Market Research Report:

Compounding Pharmacies Market: https://www.persistencemarketresearch.com/market-research/compounding-pharmacies-market.asp

Dysphagia Supplements Market: https://www.persistencemarketresearch.com/market-research/dysphagia-supplements-market.asp

Metagenomics Market: https://www.persistencemarketresearch.com/market-research/metagenomics-market.asp

Biopharmaceutical Market: https://www.persistencemarketresearch.com/market-research/biopharmaceutical-market.asp

Media Contact:
Persistence Market Research
305 Broadway,7th Floor New York City, NY 10007 United States
Call +1-646-568-7751
Call +1 800-961-0353
sales@persistencemarketresearch.com

About Us

Persistence Market Research is a U.S.-based full-service market intelligence firm specializing in syndicated research, custom research, and consulting services. Persistence Market Research boasts market research expertise across the Healthcare, Chemicals and Materials, Technology and Media, Energy and Mining, Food and Beverages, Semiconductor and Electronics, Consumer Goods, and Shipping and Transportation industries. The company draws from its multi-disciplinary capabilities and high-pedigree team of analysts to share data that precisely corresponds to clients' business needs.

This release was published on openPR.